Albert Bourla of Pfizer: worst biopharma CEO of 2023

HyacinthEmpinado/STATPfizeristhisyear’santi-EliLilly.IfDavidRicksisthebestbiopharmaCEOof2023,thenPfi ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri




leisure time

author：comprehensive    Page View：376
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： Hospitals owned by private equity see complications spike 25%
Next article： Medicare proposal to cover medical devices draws a mixed reaction